The COVID-19 antibody treatment developed by Celltrion will be supplied in earnest to nine European countries.
Celltrion Healthcare announced on the 30th that “As of the 29th, it has signed a supply contract with nine European countries for the COVID-19 antibody treatment ‘Rekkorina’ (ingredient name: Legdanvirab).”
According to Celltrion Healthcare, according to this contract, the first 150,000 vials (for 50,000 doses) will be shipped within this year. It is expected that additional orders will be placed within this year in consideration of the speed of the increase in the number of confirmed COVID-19 cases in the country and the timing of the initial supply exhaustion.
A Celltrion official said, “Consultations on export of Lekkorina are in progress with a total of 56 countries, including 9 countries. It will happen,” he said.
The countries concerned are Europe, Asia, Latin America, the Middle East, and Oceania. Previously, on the 12th (local time), Lekkona obtained an official product license from the European Commission (EC).
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
Copyright ⓒ MBN (Daily Broadcasting) Unauthorized reproduction and redistribution prohibited